ATE536369T1 - Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung - Google Patents

Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung

Info

Publication number
ATE536369T1
ATE536369T1 AT07821216T AT07821216T ATE536369T1 AT E536369 T1 ATE536369 T1 AT E536369T1 AT 07821216 T AT07821216 T AT 07821216T AT 07821216 T AT07821216 T AT 07821216T AT E536369 T1 ATE536369 T1 AT E536369T1
Authority
AT
Austria
Prior art keywords
amino acid
acid sequences
essentially
proteins
compounds containing
Prior art date
Application number
AT07821216T
Other languages
English (en)
Inventor
Ignace Joseph Isabella Lasters
Hendricus Renerus Jacobus Hoogenboom
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39015887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE536369(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ablynx Nv filed Critical Ablynx Nv
Application granted granted Critical
Publication of ATE536369T1 publication Critical patent/ATE536369T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT07821216T 2006-10-11 2007-10-11 Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung ATE536369T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85077406P 2006-10-11 2006-10-11
PCT/EP2007/060849 WO2008043821A1 (en) 2006-10-11 2007-10-11 Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof

Publications (1)

Publication Number Publication Date
ATE536369T1 true ATE536369T1 (de) 2011-12-15

Family

ID=39015887

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07821216T ATE536369T1 (de) 2006-10-11 2007-10-11 Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung

Country Status (8)

Country Link
US (2) US20100129368A9 (de)
EP (1) EP2086998B1 (de)
JP (1) JP2010505435A (de)
CN (1) CN101528767A (de)
AT (1) ATE536369T1 (de)
AU (1) AU2007306340A1 (de)
CA (1) CA2666511A1 (de)
WO (1) WO2008043821A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
AU2005269527B2 (en) 2004-07-26 2011-12-01 Pfenex Inc. Process for improved protein expression by strain engineering
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CA2685326A1 (en) 2007-04-27 2008-11-06 Dow Global Technologies Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
RU2539798C2 (ru) 2009-04-10 2015-01-27 Аблинкс Нв Улучшенные аминокислотные последовательности против il-6r и содержащие их полипептиды для лечения связанных с il-6r заболеваний и нарушений
ES2548030T3 (es) * 2009-06-01 2015-10-13 Medimmune, Llc Moléculas con semividas prolongadas y usos de las mismas
MX340541B (es) 2009-06-05 2016-07-13 Alblynx Nv Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
EP2507262A1 (de) 2009-11-30 2012-10-10 Ablynx N.V. Verbesserte gegen hrsv gerichtete aminosäuresequenzen und polypeptide damit zur prävention und/oder behandlung von atemwegsinfektionen
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
SG185354A1 (en) 2010-05-20 2012-12-28 Ablynx Nv Biological materials related to her3
MY161679A (en) 2010-07-09 2017-05-15 Affibody Ab Polypeptides
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
JP5933573B2 (ja) 2010-11-08 2016-06-15 ノバルティス アーゲー Ｃｘｃｒ２結合ポリペプチド
JP6105479B2 (ja) 2010-11-26 2017-03-29 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ 血清アルブミンに結合する設計リピートタンパク質
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
KR102072250B1 (ko) 2011-05-27 2020-03-02 아블린쓰 엔.브이. Ｒａｎｋｌ 결합 펩티드를 이용한 골 재흡수 억제
EP3363812A1 (de) * 2011-06-23 2018-08-22 Ablynx NV Verfahren für vorhersage, nachweis und verringerung von aspezifischer proteininterferenz bei tests mit variablen immunglobulin-einzeldomänen
EP3466972A1 (de) 2011-06-23 2019-04-10 Ablynx NV Serumalbumin-bindende proteine
WO2012175740A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Immunoglobulin single variable domains directed against ige
HUE031828T2 (en) 2011-06-23 2017-08-28 Ablynx Nv Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
WO2013009545A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity
EP2747783B1 (de) * 2011-09-30 2017-06-14 Ablynx N.V. Biologische stoffe im zusammenhang mit c-met
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
MX2014010495A (es) 2012-03-02 2014-11-14 Ablynx Nv Polipeptidos que enlazan a pcrv.
PT2825037T (pt) * 2012-03-16 2019-08-07 Regeneron Pharma Animais não humanos que expressam sequências de imunoglobulinas sensíveis ao ph
EP4151658A1 (de) 2012-05-07 2023-03-22 Elasmogen Limited Bindungsmoleküle mit einzeldomäne
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
JP6590695B2 (ja) 2012-09-25 2019-10-16 アフィボディ・アーベー アルブミン結合ポリペプチド
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
JP6591964B2 (ja) 2013-04-23 2019-10-16 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン Ｉｃｏｓｌへの治療上の標的特異的ｖｎａｒドメインの単離
EP3083675B1 (de) 2013-12-20 2018-03-07 Affibody AB Engineered albumin bindendes polypeptid
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
WO2018091606A1 (en) 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
WO2018132476A1 (en) 2017-01-11 2018-07-19 Bristol-Myers Squibb Company Psgl-1 antagonists and uses thereof
JP7211961B2 (ja) * 2017-03-14 2023-01-24 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡに結合する抗体
WO2019122539A1 (fr) 2017-12-22 2019-06-27 Hager-Electro Sas Appareil électrique de commutation de type modulaire
CN112638948A (zh) 2018-07-11 2021-04-09 戊瑞治疗有限公司 在酸性pH下结合至VISTA的抗体
WO2021178804A1 (en) * 2020-03-06 2021-09-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Serum albumin binding nanobody compositions and methods for using the same
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
CN116023487B (zh) * 2022-07-11 2024-03-26 南方医科大学第三附属医院（广东省骨科研究院） 与多种血清白蛋白结合的纳米抗体及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
PT1240337E (pt) * 1999-12-24 2007-01-31 Genentech Inc Métodos e composições para prolongar as meias-vidas de eliminação de compostos bioactivos
EP1377306A1 (de) * 2001-03-09 2004-01-07 Dyax Corp. Serumalbumin-bindende anteile
EP1576172A2 (de) 2002-06-21 2005-09-21 Dyax Corporation Mit serumprotein assoziierte zielspezifische liganden sowie identifizierungsverfahren dafür
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
JP4133220B2 (ja) * 2002-10-30 2008-08-13 新日本製鐵株式会社 耐久性の優れた高強度プロペラシャフトの製造方法
BRPI0316092B8 (pt) * 2002-11-08 2021-05-25 Ablynx Nv anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
EP2336179A1 (de) 2002-11-08 2011-06-22 Ablynx N.V. Stabilisierte Einzel-Domäne-Antikörper
EP2390270A1 (de) * 2003-01-10 2011-11-30 Ablynx N.V. Therapeutische Polypeptide, Homologe davon, Fragmente davon und Verwendung bei modulierender plättchenvermittelter Aggregation
EP2251357A1 (de) * 2003-11-07 2010-11-17 Ablynx N.V. Camelidae schweren Ketten Antikörpern VHHS gegen Epidermal Growth Faktor Rezeptor (EGFR) und Ihre Verwendungen
CA2583017A1 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
US20060114882A1 (en) * 2004-11-30 2006-06-01 Mills James L Presence management in packet-switched networks using circuit-switched USSD signaling
MX342271B (es) 2005-05-18 2016-09-21 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
US20070269422A1 (en) * 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
US20100166734A1 (en) * 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides

Also Published As

Publication number Publication date
US20090074770A1 (en) 2009-03-19
EP2086998A1 (de) 2009-08-12
US20100129368A9 (en) 2010-05-27
JP2010505435A (ja) 2010-02-25
CA2666511A1 (en) 2008-04-17
AU2007306340A1 (en) 2008-04-17
CN101528767A (zh) 2009-09-09
US20120148571A1 (en) 2012-06-14
EP2086998B1 (de) 2011-12-07
WO2008043821A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
ATE536369T1 (de) Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
WO2008043822A3 (en) Amino acid sequences that bind to a desired molecule in a conditional manner
WO2008028977A3 (en) Serum albumin binding proteins with long half-lives
CY1117351T1 (el) Κυτταροδιαπερατοι αναστολεις πεπτιδιων της jnk-σηματοδοτικης πορειας μεταγωγης
DK1888641T3 (da) Serumalbuminbindende proteiner
AU2002305450A1 (en) Proteomimetic compounds and methods
EA021222B8 (ru) Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
TNSN08064A1 (en) Albumin fusion proteins
ATE510011T1 (de) Neue pilzproteine und diese codierende nukleinsäuren
MX2009002816A (es) Proteinas de fusion de albumina.
DK1748701T3 (da) Fremgangsmåder og sammensætninger involverende valleproteinisolater
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
MY161664A (en) Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
WO2005017205A3 (en) Nucleic acid mapping using linear analysis
WO2008052173A8 (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
ATE514714T1 (de) Hutnfr1-selektive antagonisten
WO2007052102A3 (en) Modified green fluorescent proteins and methods for using same
ATE455792T1 (de) Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
AU7303301A (en) Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
ATE458816T1 (de) Fluoreszierendes protein aus aequorea coerulescens und ihre verwendungen
WO2008003707A3 (en) Minimized small peptides with high affinity for factor viii and factor viii-like proteins
NO20040905L (no) Peptidaktige forbindelser som selektivt binder til P-selektin, farmasoytiske preparater som inneholder peptidforbindelsene og nukleinsyrer som koder for dem.
DE602005017391D1 (de) Verwendung von peptid-mimotopen von mannosylierten lipoglycanen aus mycobacterien zur behandlung von entzündungen
WO2004110367A3 (en) Sdr proteins from staphylococcus capitis and their use in preventing and treating infections